The Value of Early Depth of Response in Predicting Long-Term Outcome in EGFR-Mutant Lung Cancer

The PFS advantage of EGFR-TKI over chemotherapy in advanced EGFR mutant NCLC is not explained by depth of response at 6 or 12 weeks. It should not be used as a surrogate of benefit in future trials or routine clinical decision making.